Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 2 Sep 2023 - 8 Sep 2023
RESEARCH TYPE:Psychology, Translational
STUDY TYPE:Human Studies, Pharmacology/Drug Development
PAIN TYPE:Psychological/Comorbidities
DATE PUBLISHED: 2023 Sep 06
JOURNAL:JAMA Psychiatry
PUBMED: 37672238
Gabapentin prescriptions have drastically increased in the US due to off-label prescribing in settings such as opioid use disorder (OUD) treatment to manage a range of comorbid conditions and withdrawal symptoms, despite a lack of evidence.
